We have developed several current Good Manufacture Practice (cGMP)-compliant induced pluripotent stem cell (iPSC) lines for clinical applications. More recently, we have developed a strategy to create hypoimmunogenic iPSC lines that combine target knock-out and knock-in of genes to generate a universal cell line that can be used to manufacture differentiated cells for multiple therapeutic applications. In addition, we have developed a safe harbor technology that allows us to rapidly express markers, reporters, factors and therapeutic products that can be delivered to target locations for prolonged and sustained delivery of biologics. In this webinar I will discuss how we move these therapeutic programs forward with both academic and pharmaceutical partners, and will focus on our effort in neurodegenerative diseases and retinal degenerative disorders.
BIO Dr. Zeng received her PhD in Molecular Biology from the Technical University of Denmark and had her postdoctoral training at the NIH. She was Professor at the Buck Institute in 2005-2018 where she built and directed the Institute’s Stem Cell Program. She has been Visiting Professor at NUS since 2018. Dr. Zeng is a recipient of several major funding including a translational grant to develop dopaminergic neurons for Parkinson’s disease from California Institute for Regenerative Medicine (https://www.cirm.ca.gov/our-progress/people/xianmin-zeng), and an induced pluripotent stem cell (iPSC)-based toxicity screen grant from the NIH. She is the Founder and Chief Executive Officer of RxCell Inc, a biotechnology company focused on therapeutic applications of iPSC.